Skip to content

James Stone

18 papers in the library · 2,488 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Stroboscopic Light Stimulation in Adults Reporting Depressive Symptoms: Safety, Tolerability, Feasibility, and Active-Comparator Development in a Staged Early-Phase Study

medRxiv Preprint Server June 17, 2026 Danny Nacker, Luise Kalus, Anil K. Seth et al. preprint

Stroboscopic light stimulation (SLS) is a candidate non-pharmacological intervention that induces transient visual and affective experiences, with potential application in depression. Before efficacy testing, clinical development requires safety, tolerability and feasibility data. We report a staged, single-site programme in adults reporting depressive symptoms. Work Package (WP) 1 tested 11...

Regional Blood Flow Signatures of Opioidergic Modulation of Ketamine in Major Depressive Disorder: A Randomized Crossover Study.

American Journal of Psychiatry June 1, 2026 Luke A. Jelen, Owen O'Daly, Fernando O Zelaya et al. 2 citations

Accumulating evidence suggests that the opioid system may modulate ketamine's rapid antidepressant effects. The objective of this study was to test whether opioid system modulation via naltrexone alters ketamine's acute effects on regional cerebral blood flow (rCBF) in major depressive disorder (MDD), and whether these changes relate to symptom measures and map onto receptor density profiles....

DOI: 10.1176/appi.ajp.20250903 (opens in new tab) Full text (opens in new tab) Depressive disorders Ketamine/esketamine Neuroimaging Psychopharmacology

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

Nature Medicine July 24, 2025 Luke A. Jelen, David J Lythgoe, James Stone et al. 29 citations

We investigated the potential role of the opioid system in modulating glutamatergic effects of ketamine administration in major depressive disorder. Twenty-six adults with major depressive disorder participated in a double-blind crossover study, receiving oral placebo or 50 mg naltrexone before an intravenous infusion of 0.5 mg per kg ketamine. Brain glutamatergic activity in the anterior...

DOI: 10.1038/s41591-025-03800-w (opens in new tab) Full text (opens in new tab) Ketamine Depression treatment Opioid system Mechanism of action

Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.

Journal of Psychoactive Drugs 2025 Morgan Hadley, Alicia Halliday, James Stone 1 citation

Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incidence and prevalence. HPPD may be more common in those with trait neuroticism. In this study, we invited hallucinogen and other drug users to complete an online questionnaire about their use of hallucinogens, their experience of HPPD symptoms, and...

N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study

Translational Psychiatry August 15, 2021 Katherine Beck, Atheeshaan Arumuham, Mattia Veronese et al.

Abstract N-methyl-D-aspartate receptor (NMDAR) hypofunction is hypothesised to underlie psychosis but this has not been tested early in illness. To address this, we studied 40 volunteers (21 patients with first-episode psychosis and 19 matched healthy controls) using PET imaging with an NMDAR selective ligand, [18F]GE-179, that binds to the ketamine binding site to index its distribution volume...

Resting-state connectivity studies as a marker of the acute and delayed effects of subanaesthetic ketamine administration in healthy and depressed individuals: A systematic review

Brain and Neuroscience Advances 2021 Vasileia Kotoula, T. Webster, James Stone et al.

Acute ketamine administration has been widely used in neuroimaging research to mimic psychosis-like symptoms. Within the last two decades, ketamine has also emerged as a potent, fast-acting antidepressant. The delayed effects of the drug, observed 2–48 h after a single infusion, are associated with marked improvements in depressive symptoms. At the systems’ level, several studies have...

Ketamine: A tale of two enantiomers

Journal of Psychopharmacology November 6, 2020 Luke A. Jelen, Allan H. Young, James Stone 244 citations

The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine, an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is arguably the most important breakthrough in depression research in the last 50 years. Ketamine remains an off-label treatment for treatment-resistant depression with factors that limit widespread use including its dissociative effects and...

Ketamine in the treatment of depression: opportunities and risks

Cutting Edge Psychiatry in Practice March 31, 2019 James Stone

There has been considerable interest in the potential of ketamine as a novel antidepressant with a unique mechanism of action. In a number of small trials, ketamine has been shown to lead to reductions in depressive symptoms within hours of administration in patients with symptoms that are otherwise refractory to treatment, with the antidepressant response lasting for days. Although the...

Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?

PeerJ 2016 Jing J Wong, Owen O'Daly, Mitul A. Mehta et al.

Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of treatment-resistant depression. In this study, we investigate whether an acute administration of ketamine leads to reductions in the functional connectivity of subgenual anterior cingulate cortex (sgACC) with other brain regions. Methods. Thirteen right-handed healthy male subjects underwent a 15...

Sensorimotor gating, cannabis use and the risk of psychosis

Schizophrenia Research May 1, 2015 Toby T Winton-Brown, V. Kumari, F. Windler et al.

Sensorimotor gating, measured as the modification of eye blink startle reflexes to loud acoustic stimuli by quieter preceding stimuli, is altered in those with psychosis, their relatives and those at high clinical risk for psychosis. Alterations have also been shown in cannabis users, albeit to a lesser extent, and cannabis is a known risk factor for the onset of psychosis in clinically and...

Drug models of schizophrenia.

Therapeutic Advances in Psychopharmacology February 1, 2015 Hannah Steeds, Robin Carhart-Harris, James Stone 132 citations

Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients....

Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis

Psychopharmacology July 19, 2014 Judith Nottage, James Stone, Robin Murray et al. 34 citations

RATIONALE: An acute challenge with delta-9-tetrahydrocannabinol (THC) can induce psychotic symptoms including delusions. High electroencephalography (EEG) frequencies, above 20 Hz, have previously been implicated in psychosis and schizophrenia. OBJECTIVES: The objective of this study is to determine the effect of intravenous THC compared to placebo on high-frequency EEG. METHODS: A double-blind...

Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

Journal of Psychopharmacology June 19, 2013 Rl Carhart-Harris, Stefan Brugger, Dj Nutt et al. 43 citations

Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the effects of five drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) in relation to psychiatric symptoms in a two-part subjective analysis. In the first part, mental health professionals...

Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation

Psychological Medicine May 24, 2013 James Stone, Helen L. Fisher, Barnaby Major et al. 69 citations

BACKGROUND: Cannabis use has been reported to be associated with an earlier onset of symptoms in patients with first-episode psychosis, and a worse outcome in those who continue to take cannabis. In general, studies have concentrated on symptoms of psychosis rather than mania. In this study, using a longitudinal design in a large naturalistic cohort of patients with first-episode psychosis, we...

DOI: 10.1017/s0033291713000883 (opens in new tab) Cannabis Psychosis Mania Schizophrenia object-oriented programming +3

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis

Schizophrenia Bulletin October 6, 2012 Robin Carhart-Harris, Robert Leech, David Erritzøe et al. 267 citations

Psilocybin is a classic psychedelic and a candidate drug model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamocortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on...

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

Journal of Psychopharmacology October 5, 2012 Amir Englund, Paul D. Morrison, Judith Nottage et al. 463 citations

Community-based studies suggest that cannabis products that are high in Δ⁹-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment...

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Proceedings of the National Academy of Sciences January 23, 2012 Alessandro Colasanti, Robin J. Tyacke, Robert Leech et al. 1,191 citations

Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about how they work in the brain. Here we used psilocybin, a classic psychedelic found in magic mushrooms, and a task-free functional MRI (fMRI) protocol designed to capture the transition from normal waking consciousness to the...

Delta-9-Tetrahydrocannabinol Disruption of Time Perception and of Self-Timed Actions

Pharmacopsychiatry July 22, 2010 James Stone, Paul D. Morrison, Judith Nottage et al. 13 citations

We tested the hypothesis that THC disrupts self-timed actions in healthy volunteers, and that this effect is related to self-rated perceptions of time distortion. We found that THC impaired subjective time perception and reduced the rate of button pressing, although the change in the rate of button pressing was more closely related to impaired concentration and intoxication. We conclude that...

DOI: 10.1055/s-0030-1255030 (opens in new tab) Time perception Delta-9-tetrahydrocannabinol Mechanism biology Δ9-tetrahydrocannabinol +2